Skadden Advises on High-Profile Pharma Deals

Skadden is involved in two recently announced, high-profile transactions in the pharmaceutical industry. We represented Schering-Plough Corporation in the tax aspects of its approximately $41 billion acquisition by Merck & Co., Inc. We also represented JP Morgan Securities, Inc., Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated and Banc of America Securities LLC as financial advisors to Pfizer Inc. in its $68 billion acquisition of Wyeth.